Showing results (411-420 of 6,286) with videos related to
Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|December 17, 2016
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysisZin Z Htike, Francesco Zaccardi, Dimitris Papamargaritis, et al.Diabetes, Obesity & Metabolism|December 22, 2007
Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator propertiesYuhao Li, Yanfei Qi, Tom H W Huang, et al.Diabetes, Obesity & Metabolism|December 22, 2007
Improvement of glycaemia control in subjects with type 2 diabetes by self-monitoring of blood glucose: comparison of two management programs adjusting bedtime insulin dosageH-S Chen, T-E Wu, T-S Jap, et al.Diabetes, Obesity & Metabolism|December 22, 2007
Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trialsS A Saha, J Molnar, R R AroraDiabetes, Obesity & Metabolism|February 6, 2008
Insulin therapy in renal diseasePedro Iglesias, Juan J DíezDiabetes, Obesity & Metabolism|February 6, 2008
Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetesD P Macfarlane, K R Paterson, M FisherDiabetes, Obesity & Metabolism|March 13, 2008
Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF ratsP J Larsen, E M Wulff, C F Gotfredsen, et al.Diabetes, Obesity & Metabolism|January 25, 2008
Metabolomic profiling of dietary-induced insulin resistance in the high fat-fed C57BL/6J mouseJ Shearer, G Duggan, A Weljie, et al.Diabetes, Obesity & Metabolism|February 14, 2008
Plasma and dietary vitamin E in relation to insulin secretion and sensitivityT Costacou, B Ma, I B King, et al.Diabetes, Obesity & Metabolism|February 14, 2008
Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expressionG B T Moore, L C Pickavance, C P Briscoe, et al.Pageof 629